FLGT

Fulgent Genetics Inc

FLGT, USA

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.

https://www.fulgentgenetics.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
FLGT
stock
FLGT

Recovery Setup Building in Ventive Hospitality Limited Experts Say - Cup and Handle Formations & Maximize Returns With Insights bollywoodhelpline.com

Read more →
FLGT
stock
FLGT

Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Average Rating of “Moderate Buy” from Analysts Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$33.6667

Analyst Picks

Strong Buy

0

Buy

1

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.73

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-0.59 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.54 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

6.02 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.08

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 52.06% of the total shares of Fulgent Genetics Inc

1.

BlackRock Inc

(7.0651%)

since

2025/06/30

2.

Millennium Management LLC

(4.7119%)

since

2025/06/30

3.

Vanguard Group Inc

(3.8092%)

since

2025/06/30

4.

Dimensional Fund Advisors, Inc.

(3.7062%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(2.0041%)

since

2025/07/31

6.

Citadel Advisors Llc

(1.9721%)

since

2025/06/30

7.

Point72 Asset Management, L.P.

(1.7801%)

since

2025/06/30

8.

State Street Corp

(1.6786%)

since

2025/06/30

9.

Geode Capital Management, LLC

(1.6771%)

since

2025/06/30

10.

iShares Russell 2000 ETF

(1.6511%)

since

2025/08/31

11.

Ameriprise Financial Inc

(1.6283%)

since

2025/06/30

12.

D. E. Shaw & Co LP

(1.5567%)

since

2025/06/30

13.

Columbia Small Cap Value Discv A

(1.1339%)

since

2025/07/31

14.

Columbia Small Cap Value Discovery Fund

(1.1029%)

since

2025/06/30

15.

Deutsche Bank AG

(1.0832%)

since

2025/06/30

16.

Nuveen, LLC

(1.0085%)

since

2025/06/30

17.

Connor Clark & Lunn Inv Mgmt Ltd

(0.997%)

since

2025/06/30

18.

Charles Schwab Investment Management Inc

(0.9782%)

since

2025/06/30

19.

Nuveen Quant Small Cap Equity R6

(0.8413%)

since

2025/07/31

20.

DFA US Targeted Value I

(0.7566%)

since

2025/07/31

21.

Morgan Stanley - Brokerage Accounts

(0.7321%)

since

2025/06/30

22.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6956%)

since

2025/07/31

23.

Fidelity Small Cap Index

(0.6896%)

since

2025/06/30

24.

Xtrackers S&P 500 Swap ETF 1C

(0.6668%)

since

2025/07/31

25.

Northern Trust Corp

(0.6548%)

since

2025/06/30

26.

Barclays PLC

(0.6455%)

since

2025/06/30

27.

BlackRock Global Equity Mkt Netrl Instl

(0.6446%)

since

2025/07/31

28.

Dimensional US Targeted Value ETF

(0.6342%)

since

2025/08/29

29.

Invenomic Institutional

(0.6308%)

since

2025/04/30

30.

iShares Russell 2000 Value ETF

(0.6119%)

since

2025/08/31

31.

Tudor Investment Corp Et AL

(0.6047%)

since

2025/06/30

32.

Jane Street Group LLC

(0.5904%)

since

2025/06/30

33.

Susquehanna International Group, LLP

(0.5553%)

since

2025/06/30

34.

DFA US Small Cap I

(0.4248%)

since

2025/07/31

35.

BlackRock Advantage Small Cap Core Instl

(0.3808%)

since

2025/07/31

36.

iShares Biotechnology ETF

(0.3782%)

since

2025/08/31

37.

Fidelity Extended Market Index

(0.3574%)

since

2025/07/31

38.

DFA US Micro Cap I

(0.3524%)

since

2025/07/31

39.

Schwab Fundamental U.S. Small CompanyETF

(0.3421%)

since

2025/08/30

40.

Vanguard Russell 2000 ETF

(0.3269%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.0602

Latest Release

Date

2025-09-30

EPS Actual

0.14

EPS Estimate

-0.22

EPS Difference

0.36

Surprise Percent

163.6364%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(4.5)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.